Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
VIVS vs PRLB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PRLB Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)
PRLB Overall Winner
6-Pillar Tally: VIVS 0 – 6 PRLB
Matrix Metrics: VIVS 0 – 10 PRLB
As of Nov 19, 2026, Proto Labs, Inc. (PRLB) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VIVS carries a Unified Composite Score of 39.0/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas PRLB carries 62.1/100 (BUY) at $62.89 (25.0x Forward P/E, 8.1% operating margin).
- Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile PRLB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About VIVS vs PRLB
VIVS
VivoSim Labs, Inc. Common Stock
$0.29
+142.92% 1D
Market Cap
$2.4M
TTM Revenue
$112,000
Forward P/E
N/M
Beta / 30D Vol
0.83β · 480% Vol
Unified Composite Score
39.0
SELL
Tech 5.0
Fund 47.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
PRLB
Head-to-Head Winner
Proto Labs, Inc.
$62.89
-1.57% 1D
Market Cap
$1.5B
TTM Revenue
$579M
Forward P/E
25.0x
Beta / 30D Vol
1.85β · 75% Vol
Unified Composite Score
62.1
BUY
Tech 78.0
Fund 69.0
Flow 54.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (VIVS 0 – 6 PRLB)
1. Valuation Multiples
PRLB
Forward P/E
N/M
25.0x
Trailing P/E
N/M
43.8x
PEG Ratio
N/M
0.86x
EV / Revenue
9.6x
2.4x
2. Growth & Scale
PRLB
Revenue Growth (YoY)
-51.4%
+14.0%
Earnings Growth (YoY)
+0.0%
+60.0%
TTM Revenue (USD)
$112,000
$579M
Market Cap
$2.4M
$1.5B
3. Profitability & Quality
PRLB
Gross Margin
N/A
45.2%
Operating Margin
-10117.0%
8.1%
Net Profit Margin
0.0%
6.0%
Return on Equity (ROE)
-343.1%
5.1%
4. Balance Sheet & Cash Flow
PRLB
Cash Generation (TTM)
-$11M EBITDA
$49M
Cash Flow Margin
N/A
8.4%
Net Cash / Leverage
$1.4M Net Cash
$130M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PRLB
Options Structure Phase
BREAKDOWN
CONSOLIDATION
Current IV / %ile
N/A (N/A)
54.0% (9th %ile)
Put/Call OI Skew
N/A
0.61x (Call-Skewed)
OBV Trend / Tech Phase
ACCUMULATION · Neutral
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
PRLB
OpEx & R&D Intensity
N/A
37.1% of Rev ($215M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Metal Fabrication Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: VIVS (0) vs PRLB (10)| Institutional Metric | VIVS | PRLB | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.4M | $1.5B | PRLB | |
| Trailing P/E Ratio | N/M | 43.8x | PRLB | |
| Forward P/E Ratio | N/M | 25.0x | PRLB | |
| Revenue Growth (YoY) | -51.4% | +14.0% | PRLB | |
| Operating Margin (TTM) | -10117.0% | 8.1% | PRLB | |
| Net Profit Margin | 0.0% | 6.0% | PRLB | |
| Return on Equity (ROE) | -343.1% | 5.1% | PRLB | |
| 52-Week Range Position | 5% ($0–$3) | 31% ($46–$100) | PRLB | |
| Beta / 30D Volatility | 0.83β · 480% Vol | 1.85β · 75% Vol | PRLB | |
| Unified Institutional Score | 39.0 / 100 (SELL) | 62.1 / 100 (BUY) | PRLB | |
| Trailing 12M Revenue (USD) | $112,000 | $579M | Scale | |
| Gross Profit Margin (TTM) | N/A | 45.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 9.6x EV/Rev | 0.86x PEG · 2.4x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$11M EBITDA ($1.4M Net Cash) | $49M ($130M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
VIVS +94.57 pp
3M Horizon
VIVS +22.92 pp
6M Horizon
PRLB +68.41 pp
1Y Horizon
PRLB +120.34 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VIVS Revenue | PRLB Revenue | VIVS Op. Margin | PRLB Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $0M | $460M | -882.4% | 17.4% | PRLB |
| FY2020 | $0M | $430M | -977.9% | 13.8% | PRLB |
| FY2021 | N/A | $490M | N/A | 8.3% | PRLB |
| FY2022 | $0M | $490M | -765.3% | -20.1% | PRLB |
| FY2023 | $0M | $500M | -4792.2% | 5.6% | PRLB |
| FY2024 | $0M | $500M | -13840.4% | 4.0% | PRLB |
| FY2025 | $0M | $530M | -8761.1% | 4.7% | PRLB |
| FY2026 | $0M | N/A | -8768.7% | N/A | VIVS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
VIVS
BREAKDOWN
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
ACCUMULATION
Exact VIVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
PRLB
CONSOLIDATION
Current IV
54.0%
IV Percentile
9th %ile
Put/Call OI Skew
0.61x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact PRLB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
VIVS Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
PRLB Moat Profile
Cyclical / Execution-Driven Positioning
Metal Fabrication Operator
OpEx & R&D Reinvestment
37.1% of Rev ($215M)
90D Engineering Disclosures
0 Published
Investor FAQ VIVS vs PRLB Key Questions & Quantitative Answers
As of Nov 19, 2026, Proto Labs, Inc. (PRLB) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VIVS carries a Unified Composite Score of 39.0/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas PRLB carries 62.1/100 (BUY) at $62.89 (25.0x Forward P/E, 8.1% operating margin). Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile PRLB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PRLB leads the Growth & Scale pillar: VIVS posts -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin), compared with PRLB at +14.0% YoY revenue growth and +60.0% YoY earnings growth on $579M TTM revenue (45.2% gross margin, 8.1% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), VIVS cumulative revenue shifted N/A while PRLB shifted +15.2%. In operating R&D and SG&A reinvestment, VIVS deploys N/A (0 90-day corporate R&D disclosures) versus 37.1% of Rev ($215M) (0 disclosures) for PRLB.
PRLB screens cheaper on headline valuation multiples. VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas PRLB trades at 25.0x Forward P/E, 43.8x Trailing P/E, 0.86x PEG, and 2.4x EV/Revenue (8.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VIVS (-343.1% ROE) versus PRLB (5.1% ROE) capital efficiency.
In options market volatility and institutional positioning, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk). By comparison, PRLB carries 54.0% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.85β · 75% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
PRLB vs VIVS · Reverse Pair
VIVS vs SSYS
· Sector Peer
VIVS vs MTLS
· Sector Peer
PRLB vs MTLS
· Sector Peer
PRLB vs SSYS
· Sector Peer
PRLB vs TREE
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem